病情快速进展对MSM HIV/AIDS患者高效抗逆转录病毒治疗后免疫重建效果的影响

覃川; 蒙新梅; 张鹏; 胡家光; 李敏基; 黄小红; 韦红卫

doi:10.16462/j.cnki.zhjbkz.2023.12.006

病情快速进展对MSM HIV/AIDS患者高效抗逆转录病毒治疗后免疫重建效果的影响

doi: 10.16462/j.cnki.zhjbkz.2023.12.006

覃川^{1, 2, 3},
蒙新梅^{1, 2, 3},
张鹏^{1, 2, 3},
胡家光^{1, 2, 3},
李敏基^{1, 2, 3},
黄小红^{1, 2, 3},
韦红卫^4, ,

1.
柳州市人民医院感染性疾病科，柳州 545006
2.
广西临床疾病生物技术研究重点实验室，柳州 545006
3.
柳州市传染病免疫研究重点实验室，柳州 545006
4.
柳州市人民医院全科医学科，柳州 545006

基金项目:

广西壮族自治区卫生和计划生育委员会自筹经费科研课题 Z20180286

详细信息

通讯作者:
韦红卫，E-mail: 13607722185@163.com

中图分类号: R512.91
计量
- 文章访问数: 104
- HTML全文浏览量: 45
- PDF下载量: 10
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-15
- 修回日期: 2022-03-27
- 刊出日期: 2023-12-10

Effect of rapid progression on immune reconstitution after highly active anti-retroviral therapy in HIV/AIDS men who have sex with men

QIN Chuan^{1, 2, 3},
MENG Xinmei^{1, 2, 3},
ZHANG Peng^{1, 2, 3},
HU Jiaguang^{1, 2, 3},
LI Minji^{1, 2, 3},
HUANG Xiaohong^{1, 2, 3},
WEI Hongwei^{4
, ,}

1.
Department of Infectious Diseases Section, Liuzhou People′s Hospital, Liuzhou 545006, China
2.
Guangxi Key Laboratory for Biotechnology of Clinical Disease, Liuzhou 545006, China
3.
Liuzhou Key Laboratory for Immunization Research of Infectious Disease, Liuzhou 545006, China
4.
General Medicine Department, Liuzhou People′s Hospital, Liuzhou 545006, China

Funds:

Guangxi Zhuang Autonomous Region Health and Family Planning Commission Self-Funded Scientific Research Project Z20180286

More Information

Corresponding author: WEI Hongwei, E-mail: 13607722185@163.com

摘要

摘要: 目的探讨病情快速进展对男男性行为者(men who have sex with men，MSM)HIV/AIDS患者高效抗逆转录病毒治疗(highly active anti-retroviral therapy, HAART)后免疫重建效果的影响。方法将108例MSM HIV/AIDS患者分为快速进展组(68例)、非快速进展组(40例)，对2组HAART启动后24个月免疫重建相关指标的恢复情况进行分析。结果随着HAART的进行，2组的CD4⁺T淋巴细胞(CD4)计数、CD4/CD8⁺T淋巴细胞(CD8)(CD4/CD8比例)比例均逐渐回升，在HAART启动后24个月，快速进展组的CD4/CD8比例(0.62±0.29)低于非快速进展组(0.84±0.33)(F=4.244, P=0.042); 快速进展组的基线CD8计数(933±430) 个/μL低于非快速进展组(1 248±476) 个/μL(t=3.515, P=0.001)，之后2组CD8计数逐渐回落至相似水平(F=0.110, P=0.741)，快速进展组的回落幅度小于非快速进展组。结论对于MSM HIV/AIDS患者，病情快速进展将对HAART免疫重建效果造成负性影响。
- 男男性行为者 /
- HIV /
- AIDS /
- 高效抗逆转录病毒治疗
Abstract: Objective To explore the effect of rapid disease progression on immune reconstitution after highly active anti-retroviral therapy (HAART) in HIV/AIDS MSM. Methods A total of 108 HIV/AIDS MSM were divided into rapid progression group (n=68) and non-rapid progression group (n=40). The recovery of immune reconstitution related indexes in two groups after HAART 24 months were statistically analyzed. Results During the progress of HAART, CD4⁺T cell (CD4) count and CD4/CD8⁺T cell (CD8) ratio in both groups gradually increased, and CD4/CD8 ratio in rapid progression group was lower than that in non-rapid progression group (0.62±0.29 vs. 0.84±0.33, F=4.244, P=0.042) after 24 months of HAART initiation. The baseline CD8 count in rapid progression group (933±430) was lower than that in non-rapid progression group (1 248±476) (t=3.515, P=0.001), and then CD8 count in both groups gradually decreased to a similar level (F=0.110, P=0.741), with smaller decline in rapid progression group than in non-rapid progression group. Conclusion For HIV/AIDS MSM, the rapid disease progression will have a negative effect on immune reconstitution of HAART.
- Men who have sex with men /
- HIV /
- AIDS /
- Highly active anti-retroviral therapy

HTML全文

表 1 2组人口学资料、WHO病情分期、初始HAART方案

Table 1. Demographic data, WHO staging, initial HAART regimen of two groups

变量Variable	快速进展组 ^①Rapid progression group ^①(n=68)	非快速进展组 ^①Non-rapid progression group ^①(n=40)	t/χ²值value	P值value
年龄/岁, (x±s) Age/year, (x±s)	31.00±10.00	28.00±9.00	0.938	0.350
婚姻状况Marriage status			0.142	0.706
未婚Unmarried	40(58.82)	25(62.50)
已婚Married	28(41.18)	15(37.50)
职业Occupation			0.422	0.516
学生Student	35(51.47)	18(45.00)
非学生Non-student	33(48.53)	22(55.00)
文化程度Education level			1.289	0.256
本科或研究生Undergraduate or graduate student	42(61.76)	29(72.50)
除本科或研究生以外文化程度 ^② Except for undergraduate or graduate student ^②	26(38.24)	11(27.50)
WHO分期WHO staging			2.231	0.315
1期、2期Phase 1, Phase 2	61(89.71)	39(97.50)
3期、4期Phase 3, Phase 4	7(10.29)	1(2.50)
初始HAART方案 ^③ Initial HAART scheme ^③			0.156	0.693
含LPV/r Containing LPV/r	18(26.47)	12(30.00)
不含LPV/r Non-containing LPV/r	50(73.53)	28(70.00)
注：HAART, 高效抗逆转录病毒治疗; CD4，CD4⁺T淋巴细胞; CD8，CD8⁺T淋巴细胞; VL，病毒载量。 ①以[人数(占比/%)]表示; ②包括专科、中专、职业高中、普通高中、初中; ③根据是否包含蛋白酶抑制剂洛匹那韦/利托那韦(Lopinavir/Ritonavir, LPV/r)，分为含LPV/r、不含LPV/r 2类; 快速进展组、非快速进展组的初始HAART方案均不包含其他蛋白酶抑制剂，不包含整合酶抑制剂及国家免费HAART药物目录之外的自费HAART药物。 Note: HAART, highly active anti-retroviral therapy; CD4, CD4⁺T cell; CD8, CD8⁺T cell; VL, viral load. ① [Number of people (proportion/%)]; ② Including junior college, technical secondary school, vocational high school, ordinary high school and junior high school; ③ According to the inclusion of protease inhibitor Lopinavir/Ritonavir(LPV/r), initial HAART scheme were divided into two categories: containing LPV/r and non-containing LPV/r, and the initial HAART regimens of rapid progress group and non-rapid progress group did not contain other protease inhibitors, integrase inhibitors and self-financed HAART drugs outside the national free HAART drug catalogue.

下载: 导出CSV

表 2 2组基线检验结果以及HAART启动后免疫重建情况

Table 2. Results of baseline tests and immune reconstitution after HAART initiation of two groups

变量Variable	HAART 启动时间/月 HAART start time/month	快速进展组 Rapid progression group (x±s)	非快速进展组 Non-rapid progression group (x±s)	2组间对比 Comparison between the two groups		协方差分析 Covariance analysis
变量Variable	HAART 启动时间/月 HAART start time/month	快速进展组 Rapid progression group (x±s)	非快速进展组 Non-rapid progression group (x±s)	t值 value	P值 value	F值 value	P值 value
CD4计数/(个·μL^-1) CD4 count /(copies·μL^-1)	0	3.84±1.14	469.00±101.00	13.224	＜0.001	― ^②	― ^②
	12	435.00±175.00 ^①	623.00±228.00 ^①	― ^②	― ^②	0.039	0.845
	24	468.00±182.00 ^①	684.00±279.00 ^①	― ^②	― ^②	0.130	0.719
CD8计数/(个·μL^-1) CD8 count /(copies·μL^-1)	0	933.00±430.00	1 248.00±476.00	3.515	0.001	― ^②	― ^②
	12	894.00±444.00 ^①	928.00±364.00 ^①	― ^②	― ^②	0.295	0.588
	24	850.00±378.00 ^①	903.00±417.00 ^①	― ^②	― ^②	0.110	0.741
CD4/CD8	0	0.29±0.19	0.43±0.19	3.583	0.001	― ^②	― ^②
	12	0.59±0.32 ^①	0.74±0.31 ^①	― ^②	― ^②	0.101	0.751
	24	0.62±0.29 ^①	0.84±0.33 ^①	― ^②	― ^②	4.244	0.042
外周血白细胞计数/(10⁹·L^-1) Peripheral blood leukocyte count/(10⁹·L^-1)	0	5.65±2.12	6.93±2.18	3.003	0.003	― ^②	― ^②
	12	5.48±1.97	6.15±1.54	― ^②	― ^②	0.417	0.520
	24	5.93±2.13	6.52±1.82	― ^②	― ^②	0.014	0.908
外周血淋巴细胞计数/(10⁹·L^-1) Peripheral blood lymphocyte count/(10⁹·L^-1)	0	1.76±0.67	2.38±0.78	5.028	＜0.001	― ^②	― ^②
	12	1.97±0.58	2.43±0.66	― ^②	― ^②	0.819	0.368
	24	2.03±0.63	2.48±0.61	― ^②	― ^②	3.113	0.081
HIV VL/(lgcopy·mL^-1)	基线Base line	3.84±1.14	3.85±1.15	0.006	0.996	― ^②	― ^②
注：HAART, 高效抗逆转录病毒治疗; CD4，CD4⁺T淋巴细胞; CD8，CD8⁺T淋巴细胞; VL，病毒载量。 ①与基线值相比，P＜0.05。② “―”代表“不适用”。 Note: HAART, highly active anti-retroviral therapy; CD4, CD4⁺T cell; CD8, CD8⁺T cell; VL, viral load. ① Compared with the baseline value, P＜0.05. ② "―" stands for "not applicable".

下载: 导出CSV

参考文献(13)

[1]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018年版)[J]. 中华内科杂志, 2018, 57(12): 867-884. DOI: 10.3760/cma.j.issn.0578-1426.2018.12.002. AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)[J]. Chin J Intern Med. 2018, 57(12): 867-884. DOI: 10.3760/cma.j.issn.0578-1426.2018.12.002.
[2]	胡文静, 张欣, 李伟华, 等. 男男性接触人群急性人类免疫缺陷病毒感染者临床特征及其与疾病进展的关系[J]. 中华传染病杂志, 2014, 32(2): 116-119. DOI: 10.3760/cma.j-issn.1000-6680.2014.02.011. Hu WJ, Zhang X, Li WH, et al. Clinical symptoms and courses among men who have sex with men with acute human immunodeficiency virus infection[J]. Chin J Infect Dis, 2014, 32(2): 116-119. DOI: 10.3760/cma.j-issn.1000-6680.2014.02.011.
[3]	张亚丽, 王伟, 吴小雪, 等. 河北省接受艾滋病抗病毒治疗的男男性行为者CD4⁺T淋巴细胞变化情况分析[J]. 医学动物防制, 2020, 36(6): 530-533. DOI: 10.7629/yxdwfz202006006. Zhang YL, Wang W, Wu XX, et al. Analysis of CD4⁺T lymphocyte changes in men who have sex with men receiving HIV/AIDS antiretroviral treatment in Hebei Province[J]. J Med Pest Control, 2020, 36(6): 530-533. DOI: 10.7629/yxdwfz202006006.
[4]	黄志征, 傅卓华, 赵秀萍, 等. 苏州市2005―2018年男男性行为人群艾滋病抗病毒治疗效果评价[J]. 江苏预防医学, 2020, 31(4): 355-358. DOI: 10.13668/j.issn.1006-9070.2020.04.001. Huang ZZ, Fu ZH, Zhao XP, et al. Curative effect evaluation on AIDS antiviral treatment among MSM in Suzhou city from 2005 to 2018[J]. Jiangsu J Prev Med, 2020, 31(4): 355-358. DOI: 10.13668/j.issn.1006-9070.2020.04.001.
[5]	辛学娟, 杨翠先, 劳云飞, 等. HIV/AIDS患者免疫重建的影响因素与促进免疫重建的治疗策略[J]. 传染病信息, 2021, 34(3): 265-269. DOI: 10.3969/j.issn.1007-8134.2021.03.016. Xin XJ, Yang CX, Lao YF, et al. Influencing factors of immune reconstitution in HIV/ AIDS patients and treatment strategies to promote immune reconstitution[J]. Infect Dis Info, 2021, 34(3): 265-269. DOI: 10.3969/j.issn.1007-8134.2021.03.016.
[6]	李彦奇, 肖丹朝, 尚翠, 等. 北京市丰台区男男性行为人群不同转介模式人类免疫缺陷病毒/获得性免疫缺陷综合征抗病毒治疗免疫学效果分析[J]. 山西医药杂志, 2023, 52(12): 897-902. DOI: 10.3969/j.issn.0253-9926.2023.12.004. Li YQ, Xiao DZ, Shang C, et al. Immunological efficacy of antiviral therapy by different referral modes among men who have sex with men with HIV/AIDS in Fengtai District of Beijing[J]. Shanxi Med J, 2023, 52(12): 897-902. DOI: 10.3969/j.issn.0253-9926.2023.12.004.
[7]	荆凡辉, 吕玮, 李太生. HIV感染者免疫功能重建新视角: CD4/CD8比值[J]. 中国艾滋病性病, 2018, 24(6): 643-644. DOI: 10.13419/j.cnki.aids.2018.06.32. Jing FH, Lyu W, Li TS, et al. A new view of CD4/CD8 ratio as an immune reconstitution marker in HIV-infected individuals[J]. Chin J AIDS STD, 2018, 24(6): 643-644. DOI: 10.13419/j.cnki.aids.2018.06.32.
[8]	刘天军, 王更新, 张曦月, 等. 379例在治HIV/AIDS病人CD4/CD8比值恢复的影响因素研究[J]. 中国艾滋病性病, 2020, 26(12): 1339-1341. DOI: 10.13419/j.cnki.aids.2020.12.18. Liu TJ, Wang GX, Zhang XY, et al. Factors influencing the recovery of CD4/CD8 ratio in 379 HIV/AIDS patients with ART[J]. Chin J AIDS STD, 2020, 26(12): 1339-1341. DOI: 10.13419/j.cnki.aids.2020.12.18.
[9]	张亚兰, 郑海潮, 卫晓丽, 等. 男男性行为人群HIV感染不同病程阶段T淋巴细胞亚型分布及稳态变化的研究[J]. 中华微生物学和免疫学杂志, 2018, 38(12): 908-913. DOI: 10.3760/cma.j.issn.0254-5101.2018.12.006. Zhang YL, Zheng HC, Wei XL, et al. Changes in CD4+T lymphocyte subset distribution and homeostasis in MSM population with different stages of HIV infection[J]. Chin J Microbiol Immunol, 2018, 38(12): 908-913. DOI: 10.3760/cma.j.issn.0254-5101.2018.12.006.
[10]	Zhang X, Zhang Z, He S, et al. FOXO3, IRF4, and xIAP are correlated with immune activation in HIV-1-infected men who have sex with men during early HIV infection[J]. AIDS Res Hum Retroviruses, 2017, 33(2): 172-180. DOI: 10.1089/AID.2015.0316.
[11]	Li L, Li XW, Ma CJ, et al. Accelerated Aging of T-Cell Subsets Among ART-Naïve HIV-Infected Chinese Men Who have Sex with Men: A Case-Control Study[J]. Curr HIV Res. 2022;20(2): 129-136. DOI: 10.2174/1570162X20666220216103504.
[12]	康文婷, 张广, 刘童童, 等. MSM人群对HIV暴露前预防知识知晓及相关因素研究[J]. 中华疾病控制杂志, 2023, 27(1): 89-94. DOI: 10.16462/j.cnki.zhjbkz.2023.01.016. Kang WT, Zhang G, Liu TT, et al. Knowledge awareness and its influencing factors of HIV pre-exposure prophylaxis among MSM[J]. Chin J Dis Control Prev, 2023, 27(1): 89-94. DOI: 10.16462/j.cnki.zhjbkz.2023.01.016.
[13]	赵亚芳, 王夏, 绳宇. 男男性行为者HIV定期检测行为的三元影响因素分析[J]. 中华疾病控制杂志, 2020, 24(12): 1433-1440. DOI: 10.16462/j.cnki.zhjbkz.2020.12.014. Zhao YF, Wang X, Sheng Y. Analysis of three factors affecting regular HIV testing among men who have sex with men[J]. Chin J Dis Control Prev, 2020, 24(12): 1433-1440. DOI: 10.16462/j.cnki.zhjbkz.2020.12.014.

施引文献

资源附件(0)

访问统计

点击查看大图

变量Variable	快速进展组 ^①Rapid progression group ^①(n=68)	非快速进展组 ^①Non-rapid progression group ^①(n=40)	t/χ²值value	P值value
年龄/岁, (x±s) Age/year, (x±s)	31.00±10.00	28.00±9.00	0.938	0.350
婚姻状况Marriage status			0.142	0.706
未婚Unmarried	40(58.82)	25(62.50)
已婚Married	28(41.18)	15(37.50)
职业Occupation			0.422	0.516
学生Student	35(51.47)	18(45.00)
非学生Non-student	33(48.53)	22(55.00)
文化程度Education level			1.289	0.256
本科或研究生Undergraduate or graduate student	42(61.76)	29(72.50)
除本科或研究生以外文化程度 ^② Except for undergraduate or graduate student ^②	26(38.24)	11(27.50)
WHO分期WHO staging			2.231	0.315
1期、2期Phase 1, Phase 2	61(89.71)	39(97.50)
3期、4期Phase 3, Phase 4	7(10.29)	1(2.50)
初始HAART方案 ^③ Initial HAART scheme ^③			0.156	0.693
含LPV/r Containing LPV/r	18(26.47)	12(30.00)
不含LPV/r Non-containing LPV/r	50(73.53)	28(70.00)
注：HAART, 高效抗逆转录病毒治疗; CD4，CD4⁺T淋巴细胞; CD8，CD8⁺T淋巴细胞; VL，病毒载量。 ①以[人数(占比/%)]表示; ②包括专科、中专、职业高中、普通高中、初中; ③根据是否包含蛋白酶抑制剂洛匹那韦/利托那韦(Lopinavir/Ritonavir, LPV/r)，分为含LPV/r、不含LPV/r 2类; 快速进展组、非快速进展组的初始HAART方案均不包含其他蛋白酶抑制剂，不包含整合酶抑制剂及国家免费HAART药物目录之外的自费HAART药物。 Note: HAART, highly active anti-retroviral therapy; CD4, CD4⁺T cell; CD8, CD8⁺T cell; VL, viral load. ① [Number of people (proportion/%)]; ② Including junior college, technical secondary school, vocational high school, ordinary high school and junior high school; ③ According to the inclusion of protease inhibitor Lopinavir/Ritonavir(LPV/r), initial HAART scheme were divided into two categories: containing LPV/r and non-containing LPV/r, and the initial HAART regimens of rapid progress group and non-rapid progress group did not contain other protease inhibitors, integrase inhibitors and self-financed HAART drugs outside the national free HAART drug catalogue.

表(2)

计量

文章访问数: 104
HTML全文浏览量: 45
PDF下载量: 10
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

病情快速进展对MSM HIV/AIDS患者高效抗逆转录病毒治疗后免疫重建效果的影响

doi: 10.16462/j.cnki.zhjbkz.2023.12.006

通讯作者: 韦红卫，E-mail: 13607722185@163.com

计量

出版历程

Effect of rapid progression on immune reconstitution after highly active anti-retroviral therapy in HIV/AIDS men who have sex with men

Corresponding author: WEI Hongwei, E-mail: 13607722185@163.com

计量

出版历程

目录

通讯作者:
韦红卫，E-mail: 13607722185@163.com